What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?
Answer from: Radiation Oncologist at Community Practice
Mainly, whether or not they've exhausted standard options. At the time I'm answering this, Pluvicto is approved for castration-resistant metastatic disease, either pre- or post-taxane chemotherapy. If they have not had chemo, I usually recommend it. If they have, I get their medical oncologist to we...
Comments
Radiation Oncologist at Comprehensive Cancer Centers of Nevada As a prior investigator on the VISION trial, I wou...
As a prior investigator on the VISION trial, I wou...